Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS) (LANA-FXII)
Factor XII-associated Cold Autoinflammatory Syndrome (FACAS) Linked to Kallikrein-kinin Pathology: Proof of Concept Treatment With Lanadelumab (DX-2930)
Sponsor: Charite University, Berlin, Germany
This PHASE2 trial investigates Hereditary Autoinflammatory Disease and is currently ongoing. Charite University, Berlin, Germany leads this study, which shows 10 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Unknown PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2023 — Feb 2024 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Sep 2022 — Mar 2023 [monthly]
Recruiting PHASE2
-
Feb 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Feb 2022 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Charite University, Berlin, Germany
- Shire International GmbH
For direct contact, visit the study record on ClinicalTrials.gov .